EDIT peer analysis
Editas Medicine (EDIT) against its competitors: price, today's move, 1-year return and market value side by side.
EDIT and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| BEAM Beam Therapeutics | $27.04 | 2.39% | 17.04% | $2.79B |
| BNTC Benitec Biopharma | $9.85 | 3.25% | -39.54% | $332.84M |
| CRBU Caribou Biosciences | $0.42 | -6.44% | -79.72% | $47.98M |
| CRSP CRISPR Therapeutics | $50.04 | -0.06% | -13.41% | $4.79B |
| DTIL Precision BioSciences | $9.69 | -8.58% | 60.12% | $296.12M |
| MGX Metagenomi Therapeutics | $0.71 | -2.93% | -67.66% | $27.61M |
| NTLA Intellia | $12.03 | 5.99% | -16.07% | $1.60B |
| PRME Prime Medicine | $4.31 | -7.31% | 5.68% | $843.40M |
| RCKT Rocket Pharmaceuticals | $2.54 | 6.50% | -28.04% | $262.25M |
| SCTX Scribe Therapeutics | $16.69 | 6.31% | – | – |
| EDIT Editas Medicine | $2.75 | 7.20% | -7.55% | $394.70M |
- EDIT's peers: BEAM (Beam Therapeutics), BNTC (Benitec Biopharma), CRBU (Caribou Biosciences), CRSP (CRISPR Therapeutics), DTIL (Precision BioSciences), MGX (Metagenomi Therapeutics), NTLA (Intellia), PRME (Prime Medicine).
Updated 2026-11-10 04:46 UTC